#### Co-development of gut microbial metabolism and visual neural circuitry over human 1 infancv 2

- 3 Kevin S. Bonham<sup>1\*</sup>, Emma T. Margolis<sup>2\*</sup>, Guilherme Fahur Bottino<sup>1</sup>, Ana Sobrino<sup>2</sup>, Fadheela Patel<sup>3</sup>, Shelley McCann<sup>1</sup>, Michal R.
- Zieff<sup>4</sup>, Marlie Miles<sup>4</sup>, Donna Herr<sup>4</sup>, Lauren Davel<sup>4</sup>, Cara Bosco<sup>2</sup>, Khula South Africa Data Collection Team<sup>†4</sup>, Curtis Huttenhower<sup>5</sup> 4
- 5 Nicolò Pini<sup>6,7</sup>, Daniel C. Alexander<sup>8</sup>, Derek K. Jones<sup>9</sup>, Steve C. R. Williams<sup>10</sup>, Dima Amso<sup>11</sup>, Melissa Gladstone<sup>12</sup>, William P. Fifer<sup>6,7</sup>, 6
  - Kirsten A. Donald<sup>3,13</sup>, Laurel J. Gabard-Durnam<sup>2</sup><sup>‡</sup>, Vanja Klepac-Ceraj<sup>1</sup><sup>‡</sup>,
- 7 \*These authors contributed equally
- † Khula South African Data Collection Team: Layla Bradford, Simone Williams, Lauren Davel, Tembeka Mhlakwaphalwa, Bokang 8
- 9 Methola, Khanyisa Nkubungu, Candice Knipe, Zamazimba Madi, Nwabisa Mlandu
- 10 ‡ co-corresponding authors
- 11 <sup>1</sup>Department of Biological Sciences, Wellesley College, Wellesley, MA, USA
- 12 <sup>2</sup>Department of Phychology, Northeastern University, Boston, MA, USA
- 13 <sup>3</sup>Division of Medical Microbiology, University of Cape Town, Cape Town, Western Cape, ZAF
- 14 <sup>4</sup>Department of Paediatrics and Child Health, University of Cape Town, Cape Town, Western Cape, ZAF
- 15 <sup>5</sup>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA
- 16 <sup>6</sup>Department of Psychiatry, Columbia University, Irving Medical Center, New York City, NY, USA
- 17 <sup>7</sup>Division of Developmental Neuroscience, New York State Psychiatric Institute, New York City, NY, USA
- <sup>8</sup>Centre for Medical Image Computing, Department of Computer Science, University College London, London, United Kingdom 18
- <sup>9</sup>Cardiff University Brain Research Imaging Centre, Cardiff University, Cardiff, Wales, United Kingdom 19
- 20 <sup>10</sup>Department of Neuroimaging, King's College London, United Kingdom
- 21 <sup>11</sup>Department of Psychology, Columbia University, New York City, NY, USA
- 22 <sup>12</sup>Department of Women and Children's Health, Institute of Life Course and Medical Science, Alder Hey Children's NHS Foundation
- 23 Trust, University of Liverpool, Liverpool, United Kingdom
- <sup>13</sup>Neuroscience Institute, University of Cape Town, Cape Town, Western Cape, ZAF 24
- 25 Running title: Infant gut microbiome and visual neurodevelopment
- 26 Keywords: visual cortex development, metagenome, infant gut microbiome, visual-evoked potential, neuroplasticity

#### 27 **ORCID** numbers:

28	Kevin S. Bonham	0000-0003-3200-7533	Emma T. Margolis	0000-0002-2036-8078
29	Guilherme Fahur Bottino	0000-0003-1953-1576	Ana Sobrino	
30	Fadheela Patel	0000-0001-5177-7416	Michal Zieff	0000-0001-9352-9947
31	Lauren Davel		Cara Bosco	
32	Curtis Huttenhower	0000-0002-1110-0096	Nicolo Pini	0000-0002-0839-6033
33	Daniel C. Alexander	0000-0003-2439-350X	Derek K. Jones	0000-0003-4409-8049
34	Steve C. R. Williams	0000-0003-4299-1941	Dima Amso	0000-0001-6798-4698
35	Melissa Gladstone	0000-0002-2579-9301	William P. Fifer	0000-0002-6936-9303
36	Shelley McCann	0000-0002-9753-7968	Kirsten A. Donald	0000-0002-0276-9660
37	Laurel J. Gabard-Durnam	0000-0002-4564-8068	Vanja Klepac-Ceraj	0000-0001-5387-5706

#### 38 Abstract

- 39 Infancy is a time of elevated neuroplasticity supporting rapid brain and sensory development. The gut
- 40 microbiome, also undergoing extensive developmental changes in early life, may influence brain
- 41 development through metabolism of neuroactive compounds. Here, we leverage longitudinal data from
- 42 194 infants across the first 18 months of life to show that microbial genes encoding enzymes play a key
- 43 role in modulating early neuroplasticity are associated with visual cortical neurodevelopment, measured
- 44 by the Visual-Evoked Potential (VEP). Neuroactive compounds included neurotransmitters GABA and
- 45 glutamate, the amino acid tryptophan, and short-chain fatty acids involved in myelination, including
- 46 acetate and butyrate. Microbial gene sets around 4 months of age were strongly associated with the VEP
- 47 from around 9 to 14 months of age and showed more associations than concurrently measured gene
- sets, suggesting microbial metabolism in early life may affect subsequent neural plasticity and
- 49 development.

#### 50 Introduction

- 51 The gut microbiome in early life has potential long-term implications for brain and body health. One
- 52 important way this influence can occur is through interactions with the central nervous system as a
- 53 "microbial-gut-brain axis" (1–3) The metabolic potential of the microorganisms that inhabit the gut vastly
- 54 exceeds that of human cells alone, with microbial genes outnumbering host genes by a hundredfold (4)
- 55 In particular, gut microbes have the ability to metabolize and synthesize many neuroactive compounds
- 56 (5). However, the physiological relevance of this in humans has been difficult to quantify, particularly
- 57 during initial neurological development in early life.
- 58 Extensive work in preclinical models suggests that these neuroactive compounds can influence the brain
- 59 through both direct and indirect pathways. For example, major neurotransmitters (e.g., glutamate, γ-
- aminobutyric acid (GABA), serotonin, and dopamine) are readily synthesized and degraded by intestinal
- 61 microbes and can enter circulation and pass the blood-brain barrier to influence central nervous function
- 62 (6–9) Glutamatergic/GABA-ergic signaling is critical for balancing the brain's excitatory and inhibitory
- 63 neurotransmission levels, and alterations in the bi-directional glutamatergic/GABA-ergic signaling
- 64 between the gut microbiome and brain are implicated in several physical and mental health conditions
- 65 (10,11). Similarly, the gut and the microbiome are critical to the regulation of metabolism for the
- 66 neurotransmitters serotonin and dopamine, particularly through the metabolism of dietary tryptophan
- 67 (12). Moreover, short-chain fatty acids (SCFAs) produced by the gut microbiome may impact the brain
- 68 directly by modulating neurotrophic factors, glial and microglial maturation and myelination, and
- 69 neuroinflammation (13,14). Other indirect pathways for gut microbial influence on the brain include vagus
- 70 nerve stimulation, neuroendocrine modulation and immune system regulation (1).
- 71 Rapidly growing literature connects the metabolic potential of the gut microbiome and brain function in
- humans (reviewed in 7,15,16), but the overwhelming majority of this research is conducted in cohorts of
- adult participants. Importantly, both the gut microbiome and the brain undergo dramatic and rapid
- 74 development over the first postnatal years (17–19) However, very little is currently known about how gut-
- 75 brain influences emerge or change during this critical window (20–22). Interrogating this early co-
- 76 development in humans is, therefore, key to both understanding adaptive gut-brain function and behavior
- and to informing strategies to support it. Specifically, the visual cortex has been shown to be sensitive to
- 78 gut microbiome modulations in adults (23) and in rodents (24), yet the visual cortex undergoes its most
- rapid period of plasticity and maturation over infancy at the same time the microbiome changes most
- 80 significantly (25–27). Visual cortical functional maturation can be robustly indexed via
- 81 electroencephalography (EEG) with the Visual-Evoked Potential (VEP) response to visual stimuli from
- 82 birth. The VEP is especially useful for indexing visual neurodevelopment as its morphology includes
- 83 amplitude deflections as well as latencies to those deflections reflecting maturation of function and
- 84 structure, respectively.

- 85 Here, we investigated the longitudinal co-development of microbial metabolic potential quantified via
- 86 genes encoding enzymes that metabolize neuroactive compounds and visual neurodevelopment as
- 87 indexed by the VEP in a longitudinal community sample of 194 infants from Gugulethu in Cape Town,
- 88 South Africa, recruited as part of the prospective longitudinal "Khula" Study (28). Stool samples and EEG
- 89 were each collected at up to 3 visits in the first 18 months of life. Shotgun metagenomic sequencing was
- 90 used to obtain microbial gene sequences from infant stool samples. To index visual cortical functional
- 91 development, latencies and peak amplitudes were extracted from each component of the VEP (i.e., first
- negative-going deflection, N1; first positive-going deflection, P1; and second negative-going deflection,
   N2), producing six VEP features of interest. We evaluated the concurrent association between microbial
- 94 genes and VEP amplitudes and latencies, and we tested prospective influences of microbial genes from
- 95 early visits on VEP changes at later visits. In this way, we were able to reveal the temporal dynamics of
- 96 gut-brain co-development within individuals during this most critical window of plasticity in both systems.

#### 97 Methods and Materials

#### 98 Cohort

#### 99 Participants and Study Design

100 Infants were recruited from local community clinics in Gugulethu, an informal settlement in Cape Town,

- 101 South Africa, as part of a prospective longitudinal study (most enrollments happened prenatally with 16%
- 102 of infants enrolled shortly after birth; 28). The first language for the majority of residents in this area is
- 103 Xhosa. Study procedures were offered in English or Xhosa depending on the language preference of the
- 104 mother. This study was approved by the relevant university Health Research Ethics Committees
- 105 (University of Cape Town study number: 666/2021). Informed consent was collected from mothers on
- behalf of themself and their infants. Demographic information, including maternal place of birth, primary
- spoken language, maternal age at enrollment, maternal educational attainment, and maternal income,
- 108 were collected at enrollment (see Table 1).
- 109 Families were invited to participate in three in-lab study visits over their infant's first two years of life. At
- the first in-lab study visit (hereafter visit-1), occurring when infants were between approximately 2 months
- and 6 months of age, the following data were collected: the infants' age (in months), sex, infant
- 112 electroencephalography (EEG), and infant stool samples.
- 113 At the second study visit (hereafter visit-2), occurring when infants were between approximately 6 months
- and 12 months of age (age in months: M=8.60, SD=1.48, range=5.41-12.00) and at the third study visit
- (hereafter visit-3), occurring when infants were between approximately 12 months and 17 months of age
- (age in months: M=14.10, SD=1.04, range=12.10-17.00), infant EEG and stool samples were collected
- again. At visits in which infants were unable to complete both EEG and stool samples on the same day,
- 118 EEG and stool samples were collected on different days. For concurrent time point analyses, infants with
- 119 EEG and stool collected more than two months apart were excluded. Not all infants had EEG and
- 120 microbiome data collected at all three time points or contributed usable data at all three-time points.
- 121 All enrolled infants received a comprehensive medical exam at each visit, which included assessments of
- 122 eye-related conditions. Several infants (n=3) were identified as having eye-related anomalies during the
- medical exam, and they were excluded from any further analyses.

#### 124 EEG Processing

#### 125 EEG Data Acquisition

- 126 Electroencephalography (EEG) data were acquired from infants while they were seated in their
- 127 caregiver's lap in a dimly-lit, quiet room using a 128-channel high density HydroCel Geodesic Sensor Net
- 128 (EGI, Eugene, OR), amplified with a NetAmps 400 high-input amplifier, and recorded via an Electrical

- 129 Geodesics, Inc. (EGI, Eugene, OR) system with a 1000 Hz sampling rate. EEG data were online
- 130 referenced to the vertex (channel Cz) through the EGI Netstation software. Impedances were kept below
- 131  $100K\Omega$  in accordance with the impedance capabilities of the high-impedance amplifiers. Geodesic
- 132 Sensor Nets with modified tall pedestals designed for improving inclusion of infants with thick/curly/tall
- 133 hair were used as needed across participants (29). Shea moisture leave-in castor oil conditioner was
- applied to hair across the scalp prior to net placement to improve both impedances and participant
- 135 comfort (29). This leave-in conditioner contains insulating ingredients, so there is no risk of electrical
- bridging, and has not been found to disrupt the EEG signal during testing (unpublished data).
- 137 Conditioning hair in this way allows for nets to lay closer to the scalp for curly/coily hair types and makes
- 138 for more comfortable net removal at the end of testing.
- 139 The Visual-Evoked Potential (VEP) taski was presented using Eprime 3.0 software (Psychology Software
- 140 Tools, Pittsburgh, PA) on a Lenovo desktop computer with an external monitor 19.5 inches on the
- 141 diagonal facing the infant (with monitor approximately 65 cm away from the infant). A standard phase-
- 142 reversal VEP was induced with a black and white checkerboard (1cm x 1 cm squares within the board)
- stimulus that alternated presentation (black squares became white, white squares became black) every
- 144 500 milliseconds for a total of 100 trials. Participant looking was monitored by video and by an assistant
- 145 throughout data collection. If the participant looked away during the VEP task, the task was rerun.

#### 146 EEG Data Pre-Processing

- 147 VEP data were exported from native Netstation .mff format to .raw format and then pre-processed using
- 148 the HAPPE+ER pipeline within the HAPPE v3.3 software, an automated open-source EEG processing
- 149 software validated for infant data (30). A subset of the 128 channels were selected for pre-processing that
- 150 excluded the rim electrodes as these are typically artifact-laden (channels excluded from pre-processing
- 151 included in Table S4). The HAPPE pre-processing pipeline was run with user-selected specifications
- 152 outlined in Table S4.
- 153 Pre-processed VEP data were considered usable and moved forward to VEP extraction if HAPPE pre-
- 154 processing ran successfully, at least 15 trials were retained following bad trial rejection, and at least one
- 155 good channel was kept within the visual ROI. Note that channels marked bad during pre-processing had
- their data interpolated as part of standard preprocessing pipelines for ERPs (30). Interpolated channels
- 157 were included in analyses here as is typically done in developmental samples, and given the low overall
- rates of interpolation present (e.g., an average of between 4 to 5 of 5 possible good channels in the
- 159 region of interest were retained at each visit time point).

#### 160 Visual-Evoked Potentials (VEPs)

- 161 VEP waveforms were extracted and quantified using the HAPPE+ER v3.3 GenerateERPs script (30).
- 162 Electrodes in the occipital region were selected as a region of interest (i.e., E70, E71, E75, E76, E83).
- 163 The VEP waveform has three main components to be quantified: a negative N1 peak, a positive P1 peak,
- and a negative N2 peak. Due to normative maturation of the waveforms as infants age, one set of user-
- specified windows for calculating component features was used for visit-1 and 2 and another was used
- 166 for visit-3. For visits 1 and 2, the window for calculating features for the N1 component was 40-100 ms,
- 167 75-175 ms for the P1 component, and 100-325 ms for the N2 component. For visit-3, the window for
- 168 calculating features for the N1 component was 35-80 ms, 75-130 ms for the P1 component, and 100-275
- ms for the N2 component. HAPPE+ER parameters used in extracting the ERPs are summarized in TableS5.
- 171 To correct for the potential influence of earlier components on later components, corrected amplitudes
- and latencies were calculated and used in all analyses. Specifically, the P1 amplitude was corrected for
- the N1 amplitude (corrected P1 amplitude = P1 N1 amplitude), the P1 latency was corrected for the N1
- 174 latency (corrected P1 latency = P1 N1 latency), the N2 amplitude was corrected for the P1 amplitude

- (corrected N2 amplitude = N2 P1 amplitude), and the N2 latency was corrected for the P1 latency
   (corrected N2 latency = N2 P1 latency).
- 177 All VEPs were visually inspected to ensure that the automatically extracted values were correct and were
- adjusted if observable peaks occurred outside the automated window bounds. Participants were
- 179 considered to have failed this visual inspection and were subsequently removed from the data set if their
- 180 VEP did not produce three discernible peaks. VEP waveforms of included participants by time point are
- 181 included in Figure 1E. 97 infants provided usable VEP data at visit-1, 130 infants provided usable VEP
- data at visit-2, and 131 infants provided usable VEP data at visit-3. For included participants, EEG data
- 183 quality metrics are summarized in Table S6. T-tests for data quality metrics (i.e., number of trials
- 184 collected, number of trials retained, number of channels retained in the ROI, Pearson's r for data pre- vs.
- post-wavelet thresholding at 5, 8, 12, and 20 Hz) were run between each visit combination (i.e., visit-1 vs.
- 186 visit-2, visit-1 vs. visit-3, visit-2 vs. visit-3). For visits that differed in data quality, follow-up post hoc
- 187 correlations were run for the data quality measure with each VEP feature at each visit in the T-test. In no
- 188 case did the data quality metric relate to VEP features at multiple visits, making it highly unlikely the data 189 quality difference contributed to results.

## 190 Biospecimens and sequencing

#### 191 Sample Collection

- 192 Stool samples (n=315) were collected in the clinic by the research assistant directly from the diaper,
- 193 transferred to Zymo DNA/RNA ShieldTM Fecal collection Tubes (#R1101, Zymo Research Corp., Irvine,
- 194 USA) and immediately frozen at -80 °C. Stool samples were not collected if the participant had taken
- 195 antibiotics within the two weeks prior to sampling.

#### 196 DNA Extraction

- 197 DNA extraction was performed at Medical Microbiology, University of Cape Town, South Africa, from stool
- 198 samples collected in DNA/RNA Shield<sup>™</sup> Fecal collection tube using the Zymo Research Fecal DNA
- 199 MiniPrep kit (# D4300, Zymo Research Corp., Irvine, USA) following manufacturer's protocol. To assess
- 200 the extraction process's quality, ZymoBIOMICS® Microbial Community Standards (#D6300 and #D6310,
- 201 Zymo Research Corp., Irvine, USA) were incorporated and subjected to the identical process as the stool
- samples. The DNA yield and purity were determined using the NanoDrop® ND -1000 (Nanodrop
- 203 Technologies Inc. Wilmington, USA).

#### 204 Sequencing

- 205 Shotgun metagenomic sequencing was performed on all samples at the Integrated Microbiome Research
- 206 Resource (IMR, Dalhousie University, NS, Canada). A pooled library (max 96 samples per run) was
- 207 prepared using the Illumina Nextera Flex Kit for MiSeq and NextSeq from 1 ng of each sample. Samples
- were then pooled onto a plate and sequenced on the Illumina NextSeq 2000 platform using 150+150 bp
- 209 paired-end P3 cells, generating 24M million raw reads and 3.6 Gb of sequence per sample (31).

#### 210 Statistics / computational analysis

#### 211 Age-Related Changes in VEP Features

- 212 To determine age-related changes in VEP features, six linear mixed models with each VEP feature as the
- 213 outcome (i.e., N1 amplitude/latency, P1 amplitude/latency, N2 amplitude/latency) were run using the Ime4
- 214 package (32) in R with age in months as the predictor of interest and number of retained trials as a
- 215 covariate.

#### 216 Metagenome processing

- 217 Raw metagenomic sequence reads (2.5 x 107 ± 1.4 x 107 reads/sample) were processed using tools
- from the bioBakery as previously described (17,33). Briefly, KneadData v0.10.0 was used with default
- 219 parameters to trim low-quality reads and remove human sequences (using reference database hg37).
- 220 Next, MetaPhIAn v3.1.0 (using database mpa\_v31\_CHOCOPhIAn\_201901) was used with default
- 221 parameters to map microbial marker genes to generate taxonomic profiles. Taxonomic profiles and raw
- 222 reads were passed to HUMAnN v3.7 to generate stratified functional profiles.

#### 223 Microbial community analysis

- 224 Principal coordinates analysis was performed in the julia programming language (34) using the
- 225 Microbiome.jl package (35). Bray-Curtis dissimilarity (Distances.jl) was calculated across all pairs of
- samples, filtering for species-level classification. Classical multidimensional scaling was performed on the
- 227 dissimilarity matrix (MultivariateStats.jl), and axes with negative eigenvalues were discarded.

#### 228 Feature Set Enrichment Analysis (FSEA)

- 229 Potentially neuroactive genesets were extracted from Supplementary Dataset 1 from (5). Gut-brain
- 230 modules provide Kegg Orthologue IDs (KOs) (36,37), which were mapped to UniRef90 IDs using the
- 231 utility mapping file provided with HUMAnN v3.1 (33). For each stool/VEP pair, logistic regression (LR)
- 232 was performed, linking the presence or absence of that UniRef in a sample with each VEP feature (i.e.,
- N1, P1, and N2 latencies and amplitudes), controlling for the age at which the stool sample was
- collected, the number of retained VEP trials, and the difference in age between the stool collection and
- 235 VEP measurement. For concurrently collected stool and VEP comparisons (Figure 2), participants whose
- stool collection and VEP measurements were more than two months apart were excluded.
- $\label{eq:uniRef} 237 \qquad \qquad UniRef \sim vep + age\_months + n\_trials + age\_diff$
- 238 FSEA was performed on each geneset that had at least five members in each comparison group
- according to the procedure set out in Subramanian et. al. (2005) (38). Briefly, enrichment scores (ES) are
- calculated based on the rank order of z-statistics from the LR for each UniRef. A permutation test was
- then performed where the ES for 5000 random samples of ranks of the same length as the gene set are
- calculated, and the pseudo-p value is the fraction of permutations where the permutation ES has a
- 243 greater absolute value than the true ES.
- 244 Benjamini-Hochberg FDR correction was performed separately on all concurrently tested geneset/VEP
- 245 feature combinations and all longitudinal geneset/VEP feature combinations. Corrected p-values (q-
- 246 values) less than 0.2 were considered statistically significant.
- 247 For longitudinal comparisons, all participants that had a stool sample collected at one visit and a VEP
- assessment at a subsequent visit were included (visit-1 stool  $\rightarrow$  visit-2 VEP, N = 84; v1  $\rightarrow$  v2, N = 76; v2
- 249  $\rightarrow$  v3, N = 69). A total of 95 geneset/VEP features were significant when using an FDR-corrected p-value
- 250 cutoff of q < 0.2. To ensure the robustness of these findings, we randomly permuted participant IDs
- 251 between the stool and VEP assessments and repeated the analysis. Over 10 random permutations, a
- 252 mean of 19.5 significant associations were identified, suggesting that FDR correction is correctly
- 253 calibrating the false-positive rate.

#### 254 Data and code availability

- 255 Code for initial processing of data and for analyses performed in this manuscript are available on github
- and archived on Zenodo (39). Input data will be archived on Dryad and downloadable via included scripts
- in analysis code upon publication.

#### 258 Results

#### 259 The brain and microbiome develop rapidly in the first months of life

260 To investigate the co-development of the gut microbiome and visual neurodevelopment, we collected

- stool and the VEP in a longitudinal cohort of 194 children in South Africa during the first 18 months of life
- 262 (Figure 1A, B, Table 1; visit-1, N = 119, age  $3.6 \pm 0.7$  months, visit-2, N = 144, age  $8.7 \pm 1.4$  months,
- visit-3, N = 130, age 14.2  $\pm$  1.0 months). As expected for children at this age (40–42), microbial
- composition was developmentally dependent, with the first principal coordinate axis for both taxonomic
- profiles (Figure 1C; variance explained = 15.1%; R = -0.50) and functional profiles (Figure 1D; variance
- explained = 12.9%; R = -0.57) driven strongly by the age of the participant at the time of collection. Similarly, both amplitude and latency VEP features were strongly correlated with age, as expected
- Similarly, both amplitude and latency VEP features were strongly correlated with age, as expected (18,41) That is, as infants got older, N1 amplitude became more negative (N1: b=-0.07, p<.05), corrected
- 269 P1 amplitude became smaller (P1: b=0.50, p<.05), corrected N2 amplitude became smaller (N2: b=0.52).
- p < .05, p > .05, p < .05,
- 271 (Figure 1E).

# 272 Microbial genes with neuroactive potential are associated with concurrently measured visual 273 development

- To test whether microbial metabolic potential was related to early life brain activity, we performed feature
- set enrichment analysis (FSEA) using previously-defined groups of potentially neuroactive microbial
- 276 genes and the concurrently measured VEP amplitude and latency features (17,5). For each gene set that
- had at least 5 genes represented in a given comparison group, logistic regression was performed using
- 278 VEP features as predictors and the presence or absence of each microbial gene in the metagenome as
- the response to determine concurrent associations (see Methods). Z statistics for in-set genes were
- 280 compared to all genes using a permutation test to determine significance of the associations as
- 281 described in Subramanian et. al., (2005) (38).
- 282 Of the 35 genesets assessed, 19 had sufficient representation to test, and of those, 18 were significantly 283 associated with at least one EEG feature during at least one visit within the 18-month window, after 284 correcting for false discovery rate (Benjamini-Hochberg, g < 0.2; Figure 2, Table S2). Microbial genes
- 285 involved in synthesis or degradation of molecules with neuroactive potential across all categories
- 286 considered (i.e., neurotransmitters, amino acid metabolism, SCFAs, other) were associated with both
- 287 VEP amplitudes and latencies at each visit, demonstrating widespread associations between early life gut
- 288 microbiome and visual cortex neurodevelopment. The number of these associations increased over time
- 289 (visit-1 had 6 associations, visit-2 had 24, and visit-3 had 37). To differentiate whether this cross-sectional
- finding indicated the early microbiome (~4 months) was sparsely related to visual cortical development at
- 4 months only or more broadly at all subsequent time points, longitudinal analyses were performed
- 292 (results below).
- 293 Specifically, across the gene sets involved in neurotransmitter synthesis and degradation, glutamate
- 294 synthesis/degradation and GABA synthesis showed associations with all VEP features, primarily at the
- 295 2nd and 3rd visit (mean ages 8.6 and 14.1 months, respectively; Table S2). Gene sets involved in
- tryptophan metabolism and associated pathways (i.e., quinolinic acid) were also strongly concurrently
- 297 related to VEP development. Specifically, tryptophan metabolism genes were associated with VEP
- 298 latencies just after each VEP component showed its greatest window of developmental change
- (components emerge sequentially as follows: P1, N1, N2), that is, of P1 at visit-1, N1 and P1 at visit-2,and N2 at visit-3.
- 301 Several short-chain fatty acid (SCFA)-metabolizing gene sets were also found to have multiple
- 302 associations with VEP features. Specifically, acetate synthesis was strongly associated with almost all
- 202 VED footures (Table S2). Butwate synthesis was associated with D1 and N2 amplitudes and latensies
- 303 VEP features (Table S2). Butyrate synthesis was associated with P1 and N2 amplitudes and latencies

- around the end of the first year of life (visits 2 and 3), when the visual cortex is most actively undergoing
- 305 myelination. Lastly, propionate synthesis/degradation was significantly associated with VEP latencies at
- every visit over the 18-month window (N1 at visits 1 and 2, and both P1 and N2 at visit-3). These SCFA
- 307 metabolizing genes showed almost double the concurrent associations with VEP latencies than
- amplitudes (11 associations with latencies, 6 associations with amplitudes).
- 309 Finally, within the remaining gene sets tested, we observed robust associations in particular between
- 310 menaquinone (Vitamin K2) gene sets and the VEP features over this infancy window. This is an expected
- relationship, as vitamin K2 specifically is posited to promote healthy vision, both outside of the brain
- through effects on the retina, and within the brain where it can protect neural circuits from oxidative stress
- 313 (43).
- Notably, across significant gene set associations with VEP features, the P1 and N2 component
- amplitudes and latencies were consistently the most sensitive to these microbial gene sets. Both P1 and
- 316 N2 components are known to show the most dramatic changes with development during the first year of
- 317 life (44) and may best reflect underlying visual learning and plasticity at this stage (Table S1).
- 318 Microbial metabolic potential predicts future brain development in infancy Given that differences in
- 319 metabolic potential of the early life microbiome may exert their effects over time, we sought to determine
- 320 whether microbial genes at early time points were associated with subsequent VEP development. To
- 321 investigate this, we performed FSEA on stool samples collected at visit-1 with visit-2 VEP (age at stool
- 322 collection =  $3.6 \pm 0.8$  months, age at VEP =  $8.6 \pm 1.5$  months) or visit-3 VEP (age at stool collection = 3.7
- $\pm 0.7$  months, age at VEP = 14.1  $\pm$  1.1 months), as well as visit-2 stool samples with visit-3 VEP (age at
- stool collection =  $8.9 \pm 1.5$  months, age at VEP =  $14.3 \pm 1.0$  months; Table S3) (Figure 3A).
- 325 All gene sets except those involved in the synthesis of 3,4-dihydroxyphenylacetic acid (DOPAC), a
- 326 metabolite of dopamine, that had a significant hit with concurrently measured VEP were also significantly
- 327 associated with at least one future VEP feature (Figure 3B, Tables 2-5). Notably, the quantity of those
- 328 associations increased substantially for all longitudinal comparisons compared to concurrent
- 329 comparisons. For example, only 6 visit-1 microbial gene sets were associated with visit-1 VEP, and each
- of those was only associated with a single concurrently measured VEP feature. By contrast, these
- 331 longitudinal analyses revealed that visit-1 microbial gene sets show a much richer pattern of associations
- 332 with future VEP feature development. Specifically, 13 visit-1 gene sets were associated with visit-2 VEP
- features, and 11 were associated with visit-3 VEP features, the majority (9/13 for visit-2, 8/11 for visit-3)
- 334 were associated with at least 2 VEP features, and nearly half (6/13 for visit-2, 5/11 for visit-3) were
- associated with more than 2 future VEP features.
- 336 Longitudinally, the early microbiome (visit-1) was related to VEP features at visit-2 and visit-3 fairly evenly
- 337 (12/28 visit-1 microbiome associations to visit-3 VEP latencies, 15/30 associations to visit-3 amplitudes),
- 338 suggesting early microbiome metabolism in the first 6 months of life is associated with visual
- 339 neurodevelopment over the next year. Microbiome metabolism from visit-2 was associated with similar
- numbers of visit-3 VEP features as visit-1 microbiome (17 visit-3 latency features, 18 visit-3 amplitude
- 341 features), suggesting continued co-development of these systems over the first postnatal year.
- 342 Neurotransmitters GABA and glutamate, tryptophan metabolism (tryptophan and quinolinic acid), SCFAs
- 343 including acetate, butyrate, and propionate, as well as menaquinone (Vitamin K2) were again all
- 344 significantly associated with multiple VEP features across multiple longitudinal comparisons.
- 345 Importantly, the nature and identity of the longitudinal associations varied over development for many
- 346 gene sets, indicating temporal specificity to these associations. With respect to the neurotransmitter-
- 347 related pathways, amongst the associations between GABA synthesis genes and future VEP features,
- 348 GABA genes specifically from visit-1 showed the greatest number of associations with future VEP
- 349 features (5/6 GABA associations) at visits 2 and 3 equally, and the majority of these associations were

- 350 VEP amplitudes (reflecting development of neurotransmission including excitatory/inhibitory balance). To
- a lesser extent, glutamate metabolism genes followed a similar temporal pattern (8/13 glutamate
- 352 associations involved visit-1 genes) but did not relate to amplitudes or latencies differentially like GABA.
- This pattern of results suggests early (within the first 6 postnatal months) microbiome GABA/glutamate dynamics, especially GABA, are most relevant for changes to visual cortex function over the following
- 355 year.
- 356 Tryptophan-related pathway genes (responsible for generating serotonin, amongst other products) from
- visit-1 were also responsible for the majority of associations with future VEP features (tryptophan: 6/8
- 358 associations; quinolinic acid: 6/9 associations). In contrast to GABA but similar to glutamate, tryptophan-
- 359 related gene associations were largely shorter-term associations with VEP features at the visit
- 360 immediately following gene set measurement (approximately 5 months later; 12/17 associations),
- 361 indicating dynamic co-development over the first 18 months of life. Across neurotransmitter-related gene
- 362 set associations (GABA, glutamate, tryptophan/serotonin), there was thus a clear pattern whereby early
- 363 (~4 months old) microbiome gene sets showed the largest number of associations with subsequent VEP
- 364 feature development.
- 365 SCFAs showed a different developmental pattern of associations with future VEP features. Specifically,
- propionate and butyrate metabolism genes from both visit-1 and visit-2 showed associations with future
- 367 VEP features, but here the effects were almost entirely observed for VEP features at visit-3 (10/10
- 368 propionate and 7/8 butyrate associations). Moreover, acetate and butyrate metabolism genes were
- 369 doubly associated with future VEP latencies compared to amplitude features.
- 370 Finally, menaquinone (Vitamin K2) metabolism genes followed a similar pattern to the SCFAs in that
- genes from visit-1 and visit-2 were largely associated with future VEP features at visit-3 (8/9
- 372 menaquinone associations). This indicates persistent associations of this early microbiome gene set with
- 373 individual differences in VEP features early in the second year of life.
- 374 It is possible that extrinsic factors related to development mutually influence both the gut microbiome and
- neural development, though we additionally tested whether VEP features were associated with microbial
- 376 metabolism at a future visit, and found substantially fewer associations (29 total associations, compared
- 377 with 95 when analyzing early stool samples with future VEP). While this does not prove a causal
- 378 relationship, it is consistent with the hypothesis that microbial metabolism influences brain development.

#### 379 Discussion

- 380 The past decade has seen a remarkable growth in our understanding of the relationships between the
- 381 developmental changes of the gut microbiome and the brain. However, a great deal of that investigation
- 382 has focused on adult populations or neuropsychiatric disorders, limiting the potential to explain how these
- associations emerge during early development. Here, we address this key open question by leveraging a
- 384 rich longitudinal dataset over the first year of life, which is the time of greatest developmental change for
- both the microbiome and brain given the unfolding of foundational sensory neurodevelopment. Our data
- 386 revealed that microbial genes involved in the metabolism of neuroactive molecules are associated with
- 387 concurrent and subsequent visual cortical neurodevelopment. These pathways included those for the
- 388 neurotransmitters GABA and glutamate, the amino acid tryptophan, and short-chain fatty acids involved
- in myelination, including acetate and butyrate.
- 390 Specifically, we have shown a robust, prospective relationship between microbial genes involved in the
- 391 metabolism of neuroactive compounds and the development of visual cortical function as measured by
- 392 the VEP electrophysiological response. We found that microbial metabolism is more strongly associated
- 393 with future measures of the VEP than those collected concurrently. While not dispositive, this would be
- the predicted outcome if microbial genes are causally influencing brain development. As additional

395 evidence for this interpretation, we did not observe the same rich set of associations in the converse

- 396 analyses examining whether VEP related to future microbiome properties. Microbial metabolism within
- 397 the first 6 months shows the most associations with subsequent visual neurodevelopment, suggesting
- 398 the early postnatal microbiome may play a particularly important role in the co-development of these systems. This interpretation is also supported by prior research showing that associations of the
- 399
- 400 microbiome with behavioral readouts of neurocognition are stronger prospectively than concurrently (45). 401 Moreover, specific associations between gene sets and VEP features showed temporal specificity within
- 402 the 18-month developmental window assessed, suggesting that the impact of early microbial metabolism
- 403 on the brain is developmentally dependent.
- 404 Notably, the gene sets most highly associated with visual functional neurodevelopment over infancy are
- 405 for the metabolism of molecules with known links to developmental neuroplasticity (46-48). Specifically,
- 406 we observed associations for gene sets related to glutamate and GABA, neurotransmitters that are
- 407 central to regulating excitatory/inhibitory (E/I) cortical balance. Developmental changes in E/I balance
- 408 modulate the degree of neuroplasticity in the mammalian cortex, including regulating the start and
- 409 progression of critical period neuroplasticity mechanisms in the visual cortex (47.46.49.50). Our observed
- 410 pattern of results suggests early (within the first 6 postnatal months) microbiome GABA/glutamate
- 411 dynamics, especially GABA, are most relevant for changes to visual cortex function over the following
- 412 year. Gut production of GABA may influence cortical GABA levels via active transport from bloodstream 413 to brain (51–53). Recent evidence suggests gut-derived glutamate may also influence brain levels and
- 414 function (8–10) and can operate via indirect mechanisms (either transformation into GABA or via
- 415 regulating glutamate levels in the bloodstream that impact glutamate transfer from brain to bloodstream).
- Tryptophan related pathway genes were also identified here that are responsible for generating serotonin 416
- 417 as well as other neuroactive molecules such as kynurenic acid (an SMDAR antagonist) (12). Both
- 418 serotonin and kynurenic acid are implicated in early neuroplasticity and neurotransmitter regulation, and
- 419 serotonin has potent effects for visual cortex plasticity in particular (54,55). While guinolinic acid is part of
- 420 the kynurenine pathway and is a neurotoxin that can cause neuronal dysfunction, it may also play a role
- 421 in glutamate uptake in the brain (56,57). Specifically, tryptophan metabolism genes were associated with
- 422 VEP latencies just after each VEP component showed its greatest window of developmental change
- 423 (components emerge sequentially as follows: P1, N1, N2), that is, of P1 at visit-1, N1 and P1 at visit-2,
- 424 and N2 at visit-3. This pathway may thus relate to processes stabilizing the neural circuitry (i.e.
- 425 downregulating neuroplasticity) underlying each VEP component, an account consistent with recently
- 426 observed effects of serotonin within the visual cortex in rodents (58). Importantly, nearly all of the body's
- 427 serotonin is produced in the gut by enterochromaffin cells, and this biosynthesis is regulated by microbes
- 428 (59,60), making this pathway an especially promising candidate intervention target for further research in 429 development.
- 430 We further found that gene sets for short-chain fatty acids important in downregulating neuroinflammation 431 and promoting myelination within the brain were robustly related to visual neurodevelopment. Myelination
- 432 is important for down-regulating plasticity in neural circuitry over development by stabilizing and
- 433 protecting circuits that have been shaped by early experience (61). Specifically, we observed
- 434 associations between acetate, butyrate, and proprionate genes with VEP development. Acetate is a
- 435 critical component required for the increased lipid synthesis that happens during postnatal myelination in
- 436 the brain (62). Circulating butyrate also increases myelination (63), and though propionate's relation to
- 437 myelinating oligodendrocytes remains unclear, it is known to protect myelinating Schwann cells outside of
- 438 the brain from oxidative stress (64). Acetate, butyrate, and propionate are all also widely regarded as
- 439 neuroprotective by promoting healthy microglial development and downregulating neuroinflammation that
- 440 interferes with myelination (65). VEP latency features reflect myelination (50,66,67), and accordingly,
- 441 these SCFAs showed more associations with VEP latency features prospectively, especially VEP latency

442 features in vsit 3. This pattern of results is consistent with these SCFA roles' in myelination occurring over

the second half of the developmental window studied. SCFAs including acetate, butyrate, and propionate

can pass the blood-brain barrier to directly influence myelination-related processes within the brain.

Taken together, the pattern of results across GABA, glutamate, tryptophan, and SCFA gene sets

suggests early postnatal microbiome-derived metabolites relate to key neuroplasticity regulation

447 processes within the cortex.

448 Our study is a substantial advancement over prior work on the microbial-gut-brain axis in early life due to 449 the sequencing method, the large number of participants, the longitudinal study design, and the inclusion 450 of participants from a previously under-represented region of the world. The use of shotgun metagenomic sequencing enables direct interrogation of microbial metabolic potential. Prior research primarily used 451 452 amplicon (16S rRNA gene) sequencing, which enables lower-resolution taxonomic identification and is 453 restricted to inferring metabolic potential based on taxonomy. Moreover, while several studies in infancy 454 have inferred gut-brain associations by linking microbiome measures to subsequent neurodevelopmental 455 measures using behavioral assessments (e.g., Bayley Scales of Infant Development), noting 456 associations with visually-mediated cognition (45), this study assessed the development of the visual 457 cortex directly using the VEP. The VEP is advantageous because features reflect largely 458 neurotransmission-related (via amplitudes) or structural (i.e., myelination, via latencies) changes over this 459 developmental window, facilitating some specificity in the observed associations. Moreover, the VEP can be indexed with fidelity from birth, providing a continuous measure of visual cortical function across the 460 461 study age-range. Additionally, this study involved a large number of participants (194) contributing dense 462 longitudinal data, with up to three time points, all taken in the first 18 months of an infant's life. While prior 463 work focused on single time point measures of microbiome and neurodevelopment (68), longitudinal 464 associations allowed us to investigate the changing relation between gut microbial metabolism and the 465 development of visual neurocircuitry over time.

466 One limitation of this study is the fact that we are only able to observe the genomic composition of the 467 microbiome, rather than the concentration of metabolites themselves. This prevents us from determining the concentration of these molecules in the gastrointestinal tract, blood, and brain, as the abundance of 468 469 these genes does not provide information about their activity, their interactions with other metabolic 470 pathways (including those of the host), or absorption by colonic epithelial cells. Moreover, the relationship 471 between gene abundance and molecule concentration may be counterintuitive, since the relationship 472 between degradation and synthesis of metabolites occurs both at the individual organism level and at the 473 community level. For example, genes for breaking down a molecule may be prevalent if that molecule is 474 at high concentrations, or the molecules may be rapidly degraded by other members of the community 475 the moment they are produced. Furthermore, it may be that the relation between metabolite and brain 476 development remains stable over time, but the relation between molecules and microbial selection 477 changes at different stages of life. Addressing these limitations in humans is challenging, even if looking 478 at stool metabolites, because overall exposure throughout the gastrointestinal tract is not necessarily 479 reflected in the final concentration of those molecules in stool. Therefore, metabolites from blood plasma 480 could provide more accurate systemic concentrations of molecules, but challenges remain on how to 481 interpret them in humans (69,70).

Given that the VEP is evolutionarily conserved in mammals and can be accurately measured during development, the hypotheses generated in humans in this study are readily testable mechanistically using in vivo models in future research. For example, VEP could be assessed in germ-free or definedmicrobiome animals (Wymore Brand et al. 2015; Kennedy, King, and Baldridge 2018) and may be supplemented with specific molecules such as SCFAs, or colonized with microbial species lacking or providing specific metabolic pathways. Furthermore, molecule concentrations in tissues from the gut to the brain can be directly assessed in these models. Uncovering relations between microbial metabolism

- and specific molecules may also generate hypotheses that can be confirmed in human data. This study,
- therefore, provides a foundation for deep investigation of the link between the human gut microbiome and
- 491 brain development.

#### 492 Acknowledgments

- 493 We would like to extend our thanks to all the caregivers and their infants who generously provided their
- time and samples for this study. We are also grateful to the dedicated nurses and researchers who
- 495 recruited participants and collected data, ensuring the success of this project. This research was
- 496 supported by the Wellcome LEAP 1kD program.

#### 497 **CRediT**

- 498 Conceptualization: KSB, ETM, KAD, LJGD, VKC
- 499 Data curation: KSB, ETM, GFB, FP, SM, MRZ, MM, DH
- 500 Formal analysis: KSB, ETM
- 501 Funding acquisition: KSB, NP, DCA, DKJ, SCRW, DA, MG, WPF, KAD, LJGD, VKC
- 502 Investigation: KSB, ETM, GFB, SM, MRZ, MM, DH
- 503 Methodology: KSB, NP, DCA, DKJ, SCRW, DA, MG, WPF, KAD, LJGD, VKC
- 504 Project administration: MRZ, MM, DH, LJGD, VKC
- 505 Software: KSB, ETM, GFB, CH, LJGD
- 506 Resources: SM, AS, FP, MRZ, MM, LD, CB, Khula, KAD, VKC
- 507 Supervision: KSB, LJGD, VKC
- 508 Validation: KSB, ETM
- 509 Visualization: KSB, ETM
- 510 Writing original draft: KSB, ETM, LJGD, VKC
- 511 Writing review & editing: KSB, ETM, CH, NP, KAD

#### 512 Author correspondence

# 513Vanja Klepac-CerajLaurel Gabard-Durnam514vklepacc@wellesley.edul.gabard-durnam@northeastern.edu515781-283-3541628 ISEC516106 Central StNortheastern University517Wellesley, MA 02481Boston, MA 02482

#### 518 **Bibliography**

- Rhee S H, Pothoulakis C, Mayer E A (2009): Principles and Clinical Implications of the Brain-Gut Enteric Microbiota Axis. *Nature Reviews Gastroenterology & Hepatology* 6: 306–314.
- 521 2. Collins S M, Surette M, Bercik P (2012): The Interplay between the Intestinal Microbiota and the Brain.
   522 *Nature Reviews Microbiology* 10: 735–742.
- 3. Brett B E, Weerth C de (2019): The Microbiota–Gut–Brain Axis: A Promising Avenue to Foster Healthy
   Developmental Outcomes. *Developmental Psychobiology* 61: 772–782.
- 4. Gilbert J A, Blaser M J, Caporaso J G, Jansson J K, Lynch S V, Knight R (2018): Current
  Understanding of the Human Microbiome. *Nature Medicine* 24: 392–400.
- 5. Valles-Colomer M, Falony G, Darzi Y, Tigchelaar E F, Wang J, Tito R Y, *et al.* (2019): The Neuroactive
  Potential of the Human Gut Microbiota in Quality of Life and Depression. *Nature microbiology* 4: 623–
  632.
- 530 6. Janik R, Thomason L A M, Stanisz A M, Forsythe P, Bienenstock J, Stanisz G J (2016): Magnetic
  531 Resonance Spectroscopy Reveals Oral Lactobacillus Promotion of Increases in Brain GABA, N-acetyl
  532 Aspartate and Glutamate. *NeuroImage* 125: 988–995.

- 7. Ahmed H, Leyrolle Q, Koistinen V, Kärkkäinen O, Layé S, Delzenne N, Hanhineva K (2022):
  Microbiota-Derived Metabolites as Drivers of Gut–Brain Communication. *Gut Microbes* 14: 2102878–
  2102879.
- 8. Matsumoto M, Kibe R, Ooga T, Aiba Y, Sawaki E, Koga Y, Benno Y (2013): Cerebral Low-Molecular
  Metabolites Influenced by Intestinal Microbiota: A Pilot Study. *Frontiers in Systems Neuroscience* 7:
  9–10.
- 9. Kawase T, Nagasawa M, Ikeda H, Yasuo S, Koga Y, Furuse M (2017): Gut Microbiota of Mice
  Putatively Modifies Amino Acid Metabolism in the Host Brain. *The British Journal of Nutrition* 117:
  775–783.
- 542 10. Filpa V, Moro E, Protasoni M, Crema F, Frigo G, Giaroni C (2016): Role of Glutamatergic
  543 Neurotransmission in the Enteric Nervous System and Brain-Gut Axis in Health and Disease.
  544 *Neuropharmacology* 111: 14–33.
- 545 11. Baj A, Moro E, Bistoletti M, Orlandi V, Crema F, Giaroni C (2019): Glutamatergic Signaling Along The
   546 Microbiota-Gut-Brain Axis. *International Journal of Molecular Sciences* 20: 1482–1483.
- 547 12. Agus A, Planchais J, Sokol H (2018): Gut Microbiota Regulation of Tryptophan Metabolism in Health
  548 and Disease. *Cell Host & Microbe* 23: 716–724.
- 549 13. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K (2019): The Role of Short-Chain Fatty Acids in
  550 Microbiota–Gut–Brain Communication. *Nature Reviews Gastroenterology & Hepatology* 16: 461–
  551 478.
- 14. Erny D, Dokalis N, Mezö C, Castoldi A, Mossad O, Staszewski O, *et al.* (2021): Microbiota-Derived
   Acetate Enables the Metabolic Fitness of the Brain Innate Immune System during Health and
   Disease. *Cell Metabolism* 33: 2260–2276.
- 15. Parker A, Fonseca S, Carding S R (2019): Gut Microbes and Metabolites as Modulators of Blood Brain Barrier Integrity and Brain Health. *Gut Microbes* 11: 135–157.
- 16. Aburto M R, Cryan J F (2024): Gastrointestinal and Brain Barriers: Unlocking Gates of
   Communication across the Microbiota–Gut–Brain Axis. *Nature Reviews Gastroenterology & Hepatology* 21: 222–247.
- 17. Bonham K, Bottino G F, McCann S H, Beauchemin J, Weisse E, Barry F, *et al.* (2023): Gut-Resident
   Microorganisms and Their Genes Are Associated with Cognition and Neuroanatomy in Children.
   *Science Advances* 9: eadi497.
- 18. Lippé S, Roy M-S, Perchet C, Lassonde M (2007): Electrophysiological Markers of Visuocortical
   Development. *Cerebral Cortex* 17: 100–107.
- 19. Dean D C, O'Muircheartaigh J, Dirks H, Waskiewicz N, Lehman K, Walker L, *et al.* (2014): Modeling
  Healthy Male White Matter and Myelin Development: 3 through 60 ~ Months of Age. *NeuroImage* 84:
  742–752.
- S68 20. Ahrens A P, Hyötyläinen T, Petrone J R, Igelström K, George C D, Garrett T J, *et al.* (2024): Infant
   Microbes and Metabolites Point to Childhood Neurodevelopmental Disorders. *Cell* 187: 1853–1873.
- 570 21. Meyer K, Lulla A, Debroy K, Shikany J M, Yaffe K, Meirelles O, Launer L J (2022): Association of the
   571 Gut Microbiota With Cognitive Function in Midlife. *JAMA Network Open* 5: e2143941.
- 572 22. Callaghan B L, Fields A, Gee D G, Gabard-Durnam L, Caldera C, Humphreys K L, *et al.* (2020): Mind
  573 and Gut: Associations between Mood and Gastrointestinal Distress in Children Exposed to Adversity.
  574 *Development and Psychopathology* 32: 309–328.

- 575 23. Canipe L G, Sioda M, Cheatham C L (2021): Diversity of the Gut-Microbiome Related to Cognitive
  576 Behavioral Outcomes in Healthy Older Adults. *Archives of Gerontology and Geriatrics* 96: 104464–
  577 104465.
- 578 24. Lupori L, Cornuti S, Mazziotti R, Borghi E, Ottaviano E, Cas M D, *et al.* (2022): The Gut Microbiota of
   579 Environmentally Enriched Mice Regulates Visual Cortical Plasticity. *Cell Reports* 38. https://doi.org/
   580 10.1016/j.celrep.2021.110212
- 25. Deen B, Richardson H, Dilks D D, Takahashi A, Keil B, Wald L L, *et al.* (2017): Organization of High Level Visual Cortex in Human Infants. *Nature Communications* 8: 13995–13996.
- 26. Ellis C T, Yates T S, Skalaban L J, Bejjanki V R, Arcaro M J, Turk-Browne N B (2021): Retinotopic
   Organization of Visual Cortex in Human Infants. *Neuron* 109: 2616–2626.
- 585 27. Kiorpes L (2015): Visual Development in Primates: Neural Mechanisms and Critical Periods.
   586 Developmental Neurobiology 75: 1080–1090.
- 28. Zieff M R, Miles M, Mbale E, Eastman E, Ginnell L, Williams S C R, *et al.* (2024): Characterizing
  Developing Executive Functions in the First 1000 Days in South Africa and Malawi: The Khula Study. *Wellcome Open Research* 9: 157–158.
- S90 29. Mlandu N, McCormick S A, Davel L, Zieff M R, Bradford L, Herr D, *et al.* (2024): Evaluating a Novel
   High-Density EEG Sensor Net Structure for Improving Inclusivity in Infants with Curly or Tightly Coiled
   Hair. *Developmental Cognitive Neuroscience* 67: 101396–101397.
- 30. Monachino A D, Lopez K L, Pierce L J, Gabard-Durnam L J (2022): The HAPPE plus Event-Related
   (HAPPE+ER) Software: A Standardized Preprocessing Pipeline for Event-Related Potential Analyses.
   *Modeling Neural Development* 57: 101140–101141.
- S1. Comeau A M, Filloramo G V (2023): Preparing Multiplexed WGS/MetaG Libraries with the Illumina
   DNA Prep Kit for the Illumina NextSeq or MiSeq. Retrieved August 14, 2024, from https://www.
   protocols.io/view/preparing-multiplexed-wgs-metag-libraries-with-the-b5z4q78w
- 32. Bates D, Mächler M, Bolker B, Walker S (2015): Fitting Linear Mixed-Effects Models Using Lme4.
   *Journal of Statistical Software* 67: 1–48.
- 33. Beghini F, McIver L J, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, *et al.* (2021): Integrating
   Taxonomic, Functional, and Strain-Level Profiling of Diverse Microbial Communities with bioBakery 3.
   *Elife* 10. https://doi.org/10.7554/eLife.65088
- 34. Bezanson J, Edelman A, Karpinski S, Shah V B (2017): Julia: A Fresh Approach to Numerical
  Computing. *Siam Review* 59: 65–98.
- 35. Bonham K, Kayisire A, Luo A, Klepac-Ceraj V (2021): Microbiome.Jl and BiobakeryUtils.Jl Julia
   Packages for Working with Microbial Community Data. *Journal of Open Source Software* 6: 3876–
   3877.
- 36. Suzek B E, Huang H, McGarvey P, Mazumder R, Wu C H (2007): UniRef: Comprehensive and Non Redundant UniProt Reference Clusters. *Bioinformatics* 23: 1282–1288.
- 37. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M (2004): The KEGG Resource for Deciphering
  the Genome. *Nucleic Acids Research* 32: D277–D280.
- 38. Subramanian A, Tamayo P, Mootha V K, Mukherjee S, Ebert B L, Gillette M A, *et al.* (2005): Gene Set
   Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression
- 615 Profiles. *Proceedings of the National Academy of Sciences* 102: 15545–15550.

- 39. Bonham K (2024, September 1): Klepac-Ceraj-Lab/EEGMicrobiome: Initial Submission. https://doi.
   org/10.5281/zenodo.13625448
- 40. Koenig J E, Spor A, Scalfone N, Fricker A D, Stombaugh J, Knight R, *et al.* (2011): Succession of
  Microbial Consortia in the Developing Infant Gut Microbiome. *Proceedings of the National Academy of Sciences of the United States of America* 4578–4585.
- 41. Yassour M, Vatanen T, Siljander H, Hämäläinen A-M, Härkönen T, Ryhänen S J, *et al.* (2016): Natural
  History of the Infant Gut Microbiome and Impact of Antibiotic Treatment on Bacterial Strain Diversity
  and Stability. *Science Translational Medicine* 8: 343–344.
- 42. Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, *et al.* (2015): Dynamics and
  Stabilization of the Human Gut Microbiome during the First Year of Life. *Cell host & microbe* 17: 690–
  703.
- 43. Li J, Lin J C, Wang H, Peterson J W, Furie B C, Furie B, *et al.* (2003): Novel Role of Vitamin K in
  Preventing Oxidative Injury to Developing Oligodendrocytes and Neurons. *Journal of Neuroscience*23: 5816–5826.
- 44. Lippe S, Kovacevic N, McIntosh R (2009): Differential Maturation of Brain Signal Complexity in the
  Human Auditory and Visual System. *Frontiers in Human Neuroscience* 3. https://doi.org/10.3389/
  neuro.09.048.2009
- 45. Carlson A L, Xia K, Azcarate-Peril M A, Goldman B D, Ahn M, Styner M A, *et al.* (2018): Infant Gut
  Microbiome Associated With Cognitive~Development. *Biological Psychiatry* 83: 148–159.
- 46. Fagiolini M, Hensch T K (2000): Inhibitory Threshold for Critical-Period Activation in Primary Visual
  Cortex. *Nature* 404: 183–186.
- 47. Hensch T K, Fagiolini M, Mataga N, Stryker M P, Baekkeskov S, Kash S F (1998): Local GABA Circuit
   Control of Experience-Dependent Plasticity in Developing Visual Cortex. *Science* 282: 1504–1508.
- 48. Takesian A E, Bogart L J, Lichtman J W, Hensch T K (2018): Inhibitory Circuit Gating of Auditory
   Critical-Period Plasticity. *Nature Neuroscience* 21: 218–227.
- 49. Gabard-Durnam L, McLaughlin K A (2020): Sensitive Periods in Human Development: Charting a
  642 Course for the Future. *Current Opinion in Behavioral Sciences* 36: 120–128.
- 50. Margolis E T, Davel L, Bourke N J, Bosco C, Zieff M R, Monachino A D, *et al.* (2024): Longitudinal
  Effects of Prenatal Alcohol Exposure on Visual Neurodevelopment over Infancy. *Developmental Psychology* 60: 1673–1698.
- 51. Takanaga H, Ohtsuki S, Hosoya Ki n, Terasaki T (2001): GAT2/BGT-1 as a System Responsible for
  the Transport of Gamma-Aminobutyric Acid at the Mouse Blood-Brain Barrier. *Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism* 21: 1232–1239.
- 52. Al-Sarraf H (2002): Transport of 14C-γ-aminobutyric Acid into Brain, Cerebrospinal Fluid and Choroid
   Plexus in Neonatal and Adult Rats. *Developmental Brain Research* 139: 121–129.
- 53. Shyamaladevi N, Jayakumar A R, Sujatha R, Paul V, Subramanian E H (2002): Evidence That Nitric
   Oxide Production Increases γ-Amino Butyric Acid Permeability of Blood-Brain Barrier. *Brain Research Bulletin* 57: 231–236.
- 54. Vetencourt J F M, Tiraboschi E, Spolidoro M, Castrén E, Maffei L (2011): Serotonin Triggers a
  Transient Epigenetic Mechanism That Reinstates Adult Visual Cortex Plasticity in Rats. *European Journal of Neuroscience* 33: 49–57.

- 55. Gu Q, Singer W (1995): Involvement of Serotonin in Developmental Plasticity of Kitten Visual Cortex.
   *European Journal of Neuroscience* 7: 1146–1153.
- 56. Lugo-Huitrón R, Ugalde Muñiz P, Pineda B, Pedraza-Chaverrí J, Ríos C, Cruz V Pérez-de la (2013):
  Quinolinic Acid: An Endogenous Neurotoxin with Multiple Targets. *Oxidative Medicine and Cellular Longevity* 2013: 104024–104025.
- 57. Tavares R G, Tasca C I, Santos C E S, Wajner M, Souza D O, Dutra-Filho C S (2000): Quinolinic Acid
   Inhibits Glutamate Uptake into Synaptic Vesicles from Rat Brain. *NeuroReport* 11: 249–250.
- 58. Hong S Z, Mesik L, Grossman C D, Cohen J Y, Lee B, Severin D, *et al.* (2022): Norepinephrine
  Potentiates and Serotonin Depresses Visual Cortical Responses by Transforming Eligibility Traces. *Nature Communications* 13: 3202–3203.
- 59. Yano J M, Yu K, Donaldson G P, Shastri G G, Ann P, Ma L, *et al.* (2015): Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis. *Cell* 161: 264–276.
- 60. Jameson K G, Hsiao E Y (2018): Linking the Gut Microbiota to a Brain Neurotransmitter. *Trends in Neurosciences* 41: 413–414.
- 61. Takesian A E, Hensch T K (2013): Balancing Plasticity/Stability across Brain Development. *Progress* 673 *in Brain Research* 207: 3–34.
- 674 62. Madhavarao C N, Arun P, Moffett J R, Szucs S, Surendran S, Matalon R, *et al.* (2005): Defective N675 acetylaspartate Catabolism Reduces Brain Acetate Levels and Myelin Lipid Synthesis in Canavan's
  676 Disease. *Proceedings of the National Academy of Sciences* 102: 5221–5226.
- 677 63. Chen T, Noto D, Hoshino Y, Mizuno M, Miyake S (2019): Butyrate Suppresses Demyelination and
  678 Enhances Remyelination. *Journal of Neuroinflammation* 16: 165–166.
- 679 64. Grüter T, Mohamad N, Rilke N, Blusch A, Sgodzai M, Demir S, *et al.* (2023): Propionate Exerts
  680 Neuroprotective and Neuroregenerative Effects in the Peripheral Nervous System. *Proceedings of the*681 *National Academy of Sciences of the United States of America* 120. https://doi.org/10.1073/pnas.
  682 2216941120
- 683 65. Caetano-Silva M E, Rund L, Hutchinson N T, Woods J A, Steelman A J, Johnson R W (2023):
  684 Inhibition of Inflammatory Microglia by Dietary Fiber and Short-Chain Fatty Acids. *Scientific Reports*685 13: 2819–2820.
- 686 Barnikol U B, Amunts K, Dammers J, Mohlberg H, Fieseler T, Malikovic A, *et al.* (2006): Pattern
  687 Reversal Visual Evoked Responses of V1/V2 and V5/MT as Revealed by MEG Combined with
  688 Probabilistic Cytoarchitectonic Maps. *NeuroImage* 31: 86–108.
- 67. You Y, Klistorner A, Thie J, Graham S L (2011): Latency Delay of Visual Evoked Potential Is a Real
   Measurement of Demyelination in a Rat Model of Optic Neuritis. *Investigative Ophthalmology & Visual Science* 52: 6911–6918.
- 68. Gao W, Salzwedel A P, Carlson A L, Xia K, Azcarate-Peril M A, Styner M A, *et al.* (2019): Gut
  Microbiome and Brain Functional Connectivity in Infants-a Preliminary Study Focusing on the
  Amygdala. *Psychopharmacology* 236: 1641–1651.
- 695 69. Deng K, Xu J-j, Shen L, Zhao H, Gou W, Xu F, *et al.* (2023): Comparison of Fecal and Blood
  696 Metabolome Reveals Inconsistent Associations of the Gut Microbiota with Cardiometabolic Diseases.
  697 *Nature Communications* 14: 571–572.

- 698 70. Dekkers K F, Sayols-Baixeras S, Baldanzi G, Nowak C, Hammar U, Nguyen D, et al. (2022): An
- 699 Online Atlas of Human Plasma Metabolite Signatures of Gut Microbiome Composition. *Nature*
- 700 *Communications* 13: 5370–5371.

### 701 Tables

	Overall (N=194)
Mean (SD) Age at EEG Data Collection (months)	
Visit 1 (N=97)	3.7 (0.85)
Visit 2 (N=129)	8.6 (1.46)
Visit 3 (N=130)	14.1 (1.03)
Mean (SD) Age at Stool Data Collection (months)	
Visit 1 (N=119)	3.6 (0.76)
Visit 2 (N=105)	8.8 (1.43)
Visit 3 (N=91)	14.0 (1.24)
Maternal Place of Birth	
South Africa	191 (98.5%)
In the African Continent (not South Africa)	3 (1.5%)
Primary Spoken Language	
Xhosa Language	187 (96.4%)
Sotho Language	2 (1.0%)
Zulu Language	1 (0.5%)
English Language	2 (1.0%)
Ndebele Language	1 (0.5%)
Afrikaans Language	1 (0.5%)
Maternal Age at Infant Birth (years)	
Mean (SD)	29.2 (5.63)
Median [Min, Max]	29.0 [18.0, 41.0
Missing	1 (0.5%)
Maternal Educational Attainment <sup>a</sup>	
Completed Grade 6 (Standard 4) to Grade 7 (Standard 5)	4 (2.1%)
Completed Grade 8 (Standard 6) to Grade 11 (Standard 9) i.e., high school without matriculating	78 (40.2%)
Completed Grade 12 (Standard 10) i.e., high school	88 (45.4%)
Part of university/ college/ post-matric education	13 (6.7%)
Completed university/ college/ post-matric education	11 (5.7%)
Maternal Monthly Income <sup>b</sup> (South African Rand/ZAR)	
Less than R1000 per month	97 (50.0%)
R1000 - R5000 per month	76 (39.2%)
R5000 - R10,000 per month	16 (8.2%)
More than R10,000 per month	0 (0%)
Unknown	5 (2.6%)
Infant Biological Sex	
Female	91 (46.9%)
Male	103 (53.1%)

Functional System is divided into grades. The equivalent in terms of standards is provided in parentheses next to each
 mentioned grade. "University/College/Post-Matric Education" refers to tertiary or post-secondary education as defined by the
 World Bank.

<sup>b</sup>At the time of writing (1/16/24), 1 US Dollar = 18.87 South African Rand (ZAR).

748	Gene set	Feature	Component	Enrichment	Q value		
749 750 751	GABA synthesis	amplitude	P1	-0.398729884	0.080789189		
751	GABA Synthesis		N2	0.366103605	0.112944828		
752 753 754	Glutamate synthesis	latency	N1	-0.282915658	0.04452		
754			P1	0.262506611	0.080789189		
755		amplitude	P1	0.231653804	0.102313043		
756 757 758	Glutamate degradation	latency	P1	0.336966501	0.159815385		
758			N2	0.325268237	0.180080899		
759		amplitude	P1	0.3256632	0.176009302		
760		latency	N1	-0.221130346	0.027257143		
761 762 763			P1	0.167147007	0.080789189		
763	Tryptophan synthesis		N2	0.19001832	0.048457143		
764		amplitude	N2	-0.163072333	0.102313043		
765	Quinolinic acid synthesis	amplitude	N1	-0.273526842	0.160915663		
766 767 768	Quinolinic acid degradation	latency	P1	0.197973559	0.102313043		
768			N2	0.195068231	0.111888889		
769		latency	N1	-0.219089592	0.029353846		
770			P1	0.192652389	0.061153846		
771	Acetate synthesis		N2	0.215744459	0.0318		
772 773 774		amplitude	P1	0.186013239	0.0742		
774			N2	-0.196033217	0.054927273		
775	Butyrate synthesis	amplitude	N1	-0.31934762	0.169849412		
776		latency	N1	0.271100718	0.122307692		
777 778 779	Isovaleric acid synthesis	omplitudo	N1	0.241218831	0.180080899		
779		amplitude	P1	-0.240952289	0.160915663		
780	Menaquinone synthesis	latency	N1	-0.139349027	0.159815385		
781 782 783	Inspital symthesis	amplitude	N1	-0.429526827	0.180430435		
	Inositol synthesis	latency	N1	-0.421912686	0.183435789		
784		amplitude	N1	-0.366578927	0.182593548		
785	p-Cresol synthesis		P1	0.452086746	0.101457143		
786			N2	-0.516450705	0.04452		
787	17-beta-Estradiol degradation	latency	N2	0.355044972	0.180080899		

#### 747 Table 2: Longitudinal FSEA, visit-1 stool ⇒ visit-2 VEP

/88	Table 3: Longitudinal FSEA, visit-1 stool ⇔ visit-3 VEP					
789	Gene set	Feature	Component	Enrichment	Q value	
790		latency	P1	0.434338693	0.04452	
791 792 793	GABA synthesis	omplitudo	P1	0.409900164	0.0742	
793		amplitude	N2	-0.506575916	0.02544	
794 795 796	Clutamata aunthasia	latency	N1	-0.303501108	0.029353846	
796	Glutamate synthesis	amplitude	N1	-0.234405478	0.111888889	
797 798 799	Tryptophan synthesis	latency	N1	-0.187530614	0.04452	
	nyptoprian synthesis	amplitude	P1	-0.217612428	0.0159	
800		latency	P1	-0.186280973	0.109392	
800 801 802	Quinolinic acid degradation		N2	-0.262447851	0.183435789	
803		amplitude	P1	-0.168943012	0.160915663	
804	Acetate synthesis	latency	N1	-0.172876999	0.080789189	
805	Propionate synthesis	amplitude	P1	0.358659876	0.080789189	
806	Propionate degradation	latency	N1	-0.509754961	0.109392	
			P1	0.534551664	0.088061538	
810 811		amplitude	P1	0.738806805	0	
806 807 808 809 810 811 812			N2	-0.666912201	0.027257143	
813 814 815	Butyrate synthesis	latency	N1	0.337326194	0.122307692	
815			N2	-0.323276487	0.149852055	
816		amplitude	P1	0.368868764	0.101457143	
817		latency	P1	0.15826763	0.087031579	
818 819 820	Menaquinone synthesis	amplitude	N1	-0.141748648	0.139740845	
820			P1	0.148803868	0.113186441	
821			N2	-0.156702017	0.102313043	
822	Inositol synthesis	amplitude	N2	-0.453803843	0.121045161	
823		latency	N1	-0.283505043	0.180430435	
824 825 826	ClpB	amplitude	P1	-0.328420633	0.112944828	
826			N2	0.35858587	0.080012903	

#### 788 Table 3: Longitudinal FSEA, visit-1 stool ⇒ visit-3 VEP

627 Table 4: Longitudinal FSEA, Visit-2 stool ⇒ Visit-3 VEP							
828	Gene set	Feature	Component	Enrichment	Q value		
829	GABA synthesis	latency	N1	-0.376215897	0.107325		
830 831 832	Glutamate synthesis	latency	N1	-0.16762197	0.160915663		
832			P1	0.297968912	0.0159		
833		amplitude	P1	0.23424529	0.03816		
834 835 836	Glutamate degradation	latency	P1	0.317418013	0.14045		
		amplitude	N2	0.282946442	0.187555102		
837 838 839	Tryptophan synthesis	amplitude	N1	-0.155489037	0.060834783		
	Typtophan Synthesis		P1	0.186539112	0.029353846		
840 841 842	Quinolinic acid synthesis	latency	N1	-0.31863828	0.061056		
842			P1	0.333137823	0.043725		
843		amplitude	P1	0.257761121	0.139182609		
844			N1	-0.16732426	0.061056		
845 846 847	Acetate synthesis	latency	P1	0.257469673	0		
847	Addite Synthesis		N2	-0.137377692	0.152983784		
848		amplitude	P1	0.146955492	0.121045161		
849	Propionate synthesis	amplitude	P1	0.299415199	0.126236364		
850 851 8523 8534 8554 8556	Propionate degradation	latency	N1	-0.550397358	0.0742		
852		latericy	N2	0.449253743	0.160915663		
854		amplitude	P1	0.50881464	0.111888889		
856		amplitude	N2	-0.422998998	0.187555102		
857		latency	N1	-0.331642845	0.080789189		
858 859 860	Butyrate synthesis		P1	0.333561852	0.0742		
860	Bulyraic Synthesis		N2	-0.290812478	0.122307692		
861		amplitude	N2	0.306668162	0.111888889		
862 863 864	Isovaleric acid synthesis	latency	P1	0.231685269	0.155652632		
864		amplitude	P1	0.246936789	0.112944828		
865		latency	N1	0.152879564	0.121045161		
866 867 868	Menaquinone synthesis	amplitude	N1	-0.164433164	0.107325		
868	menaquinene synancolo		P1	0.201456836	0.029353846		
869			N2	-0.163403497	0.112167273		
870 87 <u>1</u> 872		latency	N1	-0.638125991	0.029353846		
872	Inositol degradation		P1	0.532338179	0.101457143		
873		amplitude	P1	0.641392999	0.029353846		
874 875 876		latency	P1	0.311879942	0.139740845		
876	p-Cresol synthesis		N2	-0.31528647	0.139182609		
877		amplitude	N1	-0.303976467	0.165814286		
878 879 880	S-Adenosylmethionine synthesis	amplitude	N1	-0.222889447	0.155652632		
880			P1	0.229572468	0.13479403		
881	17-beta-Estradiol degradation	amplitude	P1	0.281861389	0.187555102		
882	ClpB	latency	P1	0.268785756	0.180430435		

#### 827 Table 4: Longitudinal FSEA, visit-2 stool ⇒ visit-3 VEP

#### 883 Figures

884 Figure 1: The gut microbiome and VEP both develop over the first 18 months of life.

- (A) Study design; participants (N=194) were seen up to 3 times over the first 18 months of life. Stool samples and EEG data were
- 886 collected, generating microbial functional profiles (stool) and VEP waveforms (EEG) used in subsequent analyses. (B) Longitudinal
- sampling of study participants; Density plots (top) for stool and EEG collection show the ages represented in each visit. The scatter
- plot (bottom) shows individual participant visits. Dotted lines connect separate visits for the same participant. When stool and EEG
- 889 data were collected for the same visit (purple) but not on the same day, dot represents the median age of collection, and vertical
- bars in blue and red represent stool and EEG collections respectively. (C) Principal coordinate analysis (PCoA) by multidimensional
   scaling (MDS) on Bray-Curtis dissimilarity of taxonomic profiles; percent variance explained (fraction of positive eigenvalues) by
- scaling (MDS) on Dray-curits dissimilarly of taxonomic promes, percent variance explained (nacion of positive eigenvalues) by
   each of the first two axes are indicated on the x and y axes respectively. (D) PCoA of microbial functional profiles (UniRef90s). (E)
- Average (solid lines) ± standard deviation (dotted lines) for VEP waveforms at each visit.
- 894 Figure 2: Concurrent feature set enrichment analysis of microbial neuroactive genes and VEP for three visits. FSEA results
- for all genesets where at least one visit had a significant hit (q < 0.2) with at least one VEP latency (A) or amplitude (B). Dots
- indicate the Z-statistic from logistic regression for each gene in a gene set. Vertical bars indicate the median Z-statistic for the gene
- set as a whole. Y-axis position for each gene set indicates visit number. Visit 1 for inositol degradation and DOPAC synthesis were
- 898 not tested, since there were fewer than 5 genes from those genesets present in the sample (See Methods).
- 899 Figure 3: Gut microbial genes predict future VEP latencies and amplitudes. (A) Age distributions for stool samples (left) and
- 900 VEP (right) for each longitudinal comparison (same individual) tested, V1 stool  $\rightarrow$  V2 VEP, V1 stool  $\rightarrow$  V3 VEP, and V2 stool  $\rightarrow$  V3
- 901 VEP. As in Figure 2, (B) and (C) show FSEA results for all genesets where at least one visit had a significant hit (q < 0.2) with at
- 902 least one VEP latency or amplitude respectively. Dots indicate the Z-statistic from logistic regression for each gene in a gene set.
- 903 Vertical bars indicate the median Z-statistic for the gene set as a whole. The Y-axis position for each gene set indicates longitudinal 904 comparison.  $V1 \rightarrow V2$  and  $V1 \rightarrow 3$  for inositol degradation and DOPAC synthesis were not tested, since there were fewer than 5
- 905 genes from those genesets present in the sample (See Methods).





